A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
Munjid Al Harthy(Sultan Qaboos University), William L. Dahut(National Cancer Institute), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Guinevere Chun(Center for Cancer Research), Daniel P. Petrylak(Yale University), Jenn Marte(National Cancer Institute), Fatima Karzai(National Institutes of Health), Joseph W. Kim(National Cancer Institute), Marc R. Theoret(United States Food and Drug Administration), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), Anna Couvillon(National Institutes of Health), Helen Owens(National Institutes of Health), Lisa M. Cordes(National Institutes of Health Clinical Center)
Cited by 3
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k